Clinical Trials

Retinal Diagnostic Center is committed to giving our patients the most up-to-date medical care possible. Our participation in clinical trials affords our patients the opportunity to receive state-of-the art-treatment or medication, before these options are available commercially. We choose to participate only in clinical trials that may offer superior treatment, in comparison to currently available treatments, and clinical trials to treat conditions that currently have no approved treatment.

Our research department is headed by Amr Dessouki, M.D. who has been the principal investigator for several national and international multi-center clinical trials. He works closely with the American Institute of Research, the Diabetic Retinopathy Clinical Research Network, FDA and several pharmaceutical companies. Drs. Monahan, Chen, Chow, He, and Gao participate as Co-investigators.

If one of our doctors believes you may benefit from being involved in a clinical trial, he will offer you the opportunity to meet with Dr. Dessouki, Dr. Chow, or Dr. He and our research team. During this visit, you will undergo a detailed explanation of the trial and the consenting process. If you choose to participate, you will be scheduled for a screening visit, which involves an extensive eye examination and general medical history to determine if you are eligible for the study. Participation in these trials is completely voluntary and free. You will not be charged for any visit or treatment related to the trial.

Our research coordinator Lynise Cummins can be reached at (408) 559-0666, ext 119, Monday through Friday from 9:00 am to 5:00 pm. If you have any questions related to the trials please feel free to contact her.

Current clinical trials:

Study Name: Ascent

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

Study Sponsor: RegenXBio

Study Status: Currently enrolling patients

Study Name: Atmosphere

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

Study Sponsor: RegenXBio

Study Status: Currently enrolling patients

Study Name: Shore

A Phase 3, Multicenter, Double-Masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration (nAMD)

Study Sponsor: Opthea

Study Status: Currently enrolling patients

Referring physicians – please see the following PDF for study summary

Study Name: Altitude

A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI_DME)

Study Sponsor: RegenXBio

Study Status: Closed

Study Name: Elevatum

A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Closed

Study Name: Davio2

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

Study Sponsor: EyePoint Pharmaceuticals, Inc.

Study Status: Closed

Study Name: Longitude

A Longitudinal, Biomarker Study of Anti-VEGF, to Explore the Relationship Between Aqueous Humor Composition and Multimodal Retinal Imaging in Neovascular Age-Related macular Degeneration and Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Comino

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Closed

Study Name: Balaton

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Mylight

A 52-Week Multicenter, Randomized, Double-Masked 2-Arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea, Administered Intravitreally, In Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: Sandoz Biopharmaceuticals

Study Status: Completed

Study Name: Gale

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Sponsor: Apellis Pharmaceuticals

Study Status: Closed

Study Name: Photon

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema

Study Sponsor: Regeneron Pharmaceuticals

Study Status: Closed

Study Name: GEM-CL-10311

A Multicenter, Multiple-Dose Study in Neovascular Age-Related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct Standard of Care Aflibercept Therapy

Study Sponsor: Gemini Therapeutics

Study Status: Completed

Study Name: Rhone-X

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Closed

Study Name: Avonelle-X

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Closed

Study Name: Gather2

A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled, Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Sponsor: IVERIC bio

Study Status: Closed

Study Name: Catalina

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Study Sponsor: NGM Biopharmaceuticals

Study Status: Completed

Study Name: SCD411-CP101

A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea in Subjects with Neovascular Age-Related Macular Degeneration

Study Sponsor: SamChunDang Pharm Co

Study Status: Completed

Study Name: Oaks

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Study Sponsor: Apellis Pharmaceuticals

Study Status: Completed

Study Name: Tenaya

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: F. Hoffmann-La Roche Ltd.

Study Status: Completed

Study Name: Yosemite

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd.

Study Status: Completed

This is a list of past clinical trials that Retinal Diagnostic Center was a part of (you can find more detailed information on the web at clinicaltrials.gov):

Study Name: Kingfisher

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 Weeks Versus Aflibercept

Study Sponsor: Novartis Pharmaceuticals

Study Status: Completed

Study Name: Ionis

A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Study Sponsor: Ionis Pharmaceuticals

Study Status: Completed

Study Name: Altissimo

A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-Acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-Related Macular Degeneration

Study Sponsor: Graybug Vision

Study Status: Completed

Study Name: Norse Two

A Clinical Effectiveness, Multicenter, Randomized, Double-Masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoval Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration

Study Sponsor: Outlook Therapeutics

Study Status: Completed

Study Name: DRCR - Protocol AH

Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole

Study Sponsor: DRCR

Study Status: Completed

Study Name: DRCR - Protocol AG

Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction

Study Sponsor: DRCR

Study Status: Completed

Study Name: Panda-1

Phase 3 - A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

Study Sponsor: Chengdu Kanghong Biotechnology

Study Status: Completed

Study Name: Protocol AC

Randomized Trial of Intravitreous Aflibercept versus Intravitrteous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Completed

Study Name: Topaz

Phase 3 - A Randomized, Masked, Controlled Trial To Study The Safety and Efficacy of Suprachoiroidal CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion

Study Sponsor: Clearside

Study Status: Completed

Study Name: Insight

A Multi-Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eyelea in Subjects with Diabetic Macular Edema

Study Sponsor: Mylan

Study Status: Completed

Study Name: OPH2003

Phase 2B - A Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Study Sponsor: Ophthotech

Study Status: Completed

Study Name: Protocol AD

PRIMENT- Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate versus Placebo

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Completed

Study Name: SEQUOIA

Phase 3 - Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration

Study Sponsor: Allergan

Study Status: Completed

Study Name: Mako (Ohr-1601)

A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

Study Sponsor: Ohr Pharmaceutical

Study Status: Completed

Avenue (BP29647)

Phase 2, 36 weeks study comparing RO6867461 to Lucentis for Neovascular Age-related Macular Degeneration

Study Sponsor: Roche/Genentech

Study Status: Completed

Proxima A (GX29633)

A multicenter, prospective epidemiologic study of the progression of geographic atrophy secondary to age-related macular degeneration.

Study Sponsor: Roche/Genentech

Study Status: Completed

CIRCLE

Phase 2, Randomized, Double-masked, Sham Controlled, Multi-center study to Evaluate the Efficacy and Safety of Ocriplasmin (Jetrea) in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects with Non-Proliferative Diabetic Retinopathy. (NPDR)

Study Sponsor: Thrombogenic

Study Status: Completed

OLE (GX29198)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy who have completed Genentech sponsored Lampalizumab studies.

Study Sponsor: Roche/Genentech

Study Status: Completed

Acacia (150998-007)

AbiCipar pegol safety and efficacy in Patients with Centrally-Involved Diabetic macular edema

Study Sponsor: Allergan

Study Status: Completed

Study Name: DRCR Protocol AB

Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Completed

Study Name: Exposure (GX29455)

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Adminstered Every Two Weeks or Every Four Weeks to Patients with Geographic Atrophy.

Study Sponsor: Roche/Genentech

Study Status: Completed

Study Name: DRCR-Protocol V

A prospective study comparing 3 treatment options (Anti-VEGF injections vs. focal laser vs. observation) in patients with diabetic macular edema AND excellent vision (20/25 or better)

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Completed

Study Name: Ocriplasmin Research to Better Inform Treatment (ORBIT)

Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes

Study Sponsor: ThromboGenics

Study Status: Completed

Study Name: B1261009

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (Oral Pill) With Ranibizumab In Adults With Diabetic Macular Edema

Study Sponsor: Pfizer

Study Status: Completed

Study Name: HORIZON

A study to evaluate Ranizumab in subjects with choroidal neovascularization secondary to age-related macular degeneration or macular edema secondary to retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Completed

Study Name: MIVI-TRUST

A trial of microplasmin intravitreal injection for non-surgical treatment of focal vtireomacular adhesion.

Study Sponsor: Thrombogenics

Study Status: Completed

Study Name: DRCR-Protocol S

Diabetic retinopathy clinical research network prompt pan retinal photocoagulation versus intravitreal ranizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy.

Study Sponsor: DRCR

Study Status: Completed

Study Name: Ophthotech Fovista

A phase 3 study comparing intravitreal Fovista (Anti PDGF-B Pegylated Aptamer) in combination with Lucentis vs. Lucentis alone in patients with wet macular degeneration.

Study Sponsor: Ophthotech Corporation

Study Status: Completed

Study Name: L-Path

A phase 2A study comparing a new medication called Sonepcizumab (iSONEPTM [LT1009]) to standard treatment (Eylea, Lucentis, or Avastin) in refractory exudative (wet) Age-Related Macular Degeneration

Study Sponsor: L-Path, Inc

Study Status: Completed

Study Name: HARBOR

A study to test the efficacy and safety of Ranizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal, neovascular age-related macular degeneration.

Study Status: Completed

Study Name: CABERNET

A study of locally applied radiation therapy for the treatment of exudative (wet) macular degeneration

Study Sponsor: Neovista

Study Status: Completed

Study Name: RADICAL

A study of combination therapy using photodynamic therapy, Lucentis(R) and Dexamethasone for the treatment of exudative (wet) macular degeneration.

Study Sponsor: QLT

Study Status: Completed

Study Name: VIEW1

A study of VEGF-trap injection for the treatment of exudative (wet) macular degeneration.

Study Sponsor: Regeneron

Study Status: Completed

Study Name: RISE

A study of Lucentis(R) injection for the treatment of diabetic macular edema.

Study Sponsor: Genentech

Study Status: Completed

Study Name: CRUISE

A study of Lucentis(R) injection for the treatment of macular edema due to central retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Completed

Study Name: BRAVO

A study of Lucentis(R) injection for the treatment of macular edema due to branch retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Completed